Home LiteratureArticle Details
PMID: 1519660 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review

Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm.

The American journal of pathology ·Vol. 141 ·No. 3 ·1992-09-00 ·Pages 519-24

Kerbel RS

Abstract

Evidence is briefly reviewed, primarily in the context of human melanoma, which suggests that acquisition of resistance to multiple, structurally diverse, growth inhibitory cytokines occurs during malignant tumor progression. A similar pleiotrophy appears to occur with respect to growth factor independence. Also discussed is the notion that growth factors that behave as inhibitors for early-stage, benign tumor cells can 'switch' so as to function as mitogens for tumor cells from more advanced stages of disease progression, i.e., when the cells acquire competence for metastasis. The combined phenotypes of 'multicytokine resistance' and 'multi-growth factor independence' help provide tumor cells with the competence to grow in the mesenchymes of the primary organ site and in distant organs.

MeSH Terms
Cytokines/physiology Drug Resistance Growth Substances/physiology Humans Melanoma/pathology,physiopathology,secondary Neoplasm Metastasis Neoplasm Staging Neoplasms/pathology,physiopathology
Chemicals
Cytokines Growth Substances
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Kerbel R S
Cancer Research Division, Sunnybrook Health Science Center, Toronto, Ontario, Canada.
References (44)
44 references, click to expand
  1. Autocrine secretion and malignant transformation of cells.
    N Engl J Med. 1980 Oct 9;303(15):878-80 PMID: 7412807
  2. bFGF as an autocrine growth factor for human melanomas.
    Oncogene Res. 1988 Sep;3(2):177-86 PMID: 3226725
  3. Growth factors and cancer.
    Science. 1991 Nov 22;254(5035):1146-53 PMID: 1659742
  4. Studies on the interaction between interleukin 6 and human malignant nonhematopoietic cell lines.
    Cancer Res. 1991 Aug 1;51(15):3862-6 PMID: 1855204
  5. Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines.
    J Clin Invest. 1991 Aug;88(2):696-9 PMID: 1864979
  6. Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors.
    Int J Cancer. 1987 Nov 15;40(5):687-90 PMID: 3316051
  7. Biology of tumor progression in human melanocytes.
    Lab Invest. 1987 May;56(5):461-74 PMID: 3553733
  8. Growth regulation of human melanocytes: mitogenic factors in extracts of melanoma, astrocytoma, and fibroblast cell lines.
    Science. 1985 Sep 6;229(4717):984-6 PMID: 4023718
  9. Transforming growth factor beta 1 (TGF-beta 1) inhibits retinoblastoma gene expression but not pRB phosphorylation in TGF-beta 1-growth stimulated colon carcinoma cells.
    Oncogene. 1992 Apr;7(4):801-5 PMID: 1565477
  10. Enhanced expression of interleukin-6 in primary human renal cell carcinomas.
    J Natl Cancer Inst. 1991 Nov 20;83(22):1668-72 PMID: 1749019
  11. Effects of MGSA/GRO alpha on melanocyte transformation.
    Oncogene. 1991 Jul;6(7):1115-24 PMID: 1861861
  12. TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis.
    Int J Cancer. 1991 Aug 19;49(1):129-39 PMID: 1874566
  13. Multiple growth factor independence in rat mammary carcinoma cells.
    Breast Cancer Res Treat. 1991 May;18(2):73-81 PMID: 1912610
  14. The pathogenic role of growth factors in melanoma.
    Semin Dermatol. 1991 Sep;10(3):246-55 PMID: 1931574
  15. Isolation of human colon carcinoma cells for resistance to a single interferon associated with cross-resistance to multiple recombinant interferons: alpha, beta, and gamma.
    J Natl Cancer Inst. 1990 Mar 21;82(6):517-22 PMID: 2138228
  16. The cell biology of transforming growth factor beta.
    Biochim Biophys Acta. 1990 Jun 1;1032(1):79-87 PMID: 2194569
  17. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures.
    Cancer Res. 1990 Nov 1;50(21):6959-65 PMID: 2208162
  18. Role of transforming growth factor beta 1 in induction of colon carcinoma differentiation by hexamethylene bisacetamide.
    Cancer Res. 1990 Jan 15;50(2):261-5 PMID: 2295065
  19. Inhibition of carcinoma and melanoma cell growth by type 1 transforming growth factor beta is dependent on the presence of polyunsaturated fatty acids.
    Proc Natl Acad Sci U S A. 1990 Jul;87(14):5543-7 PMID: 2371287
  20. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor.
    EMBO J. 1989 Dec 1;8(12):3685-91 PMID: 2684645
  21. Autoregulation of MeWo metastatic melanoma cell growth: characterization of intracellular (FGF, MGSA) and secreted (PDGF) growth factors.
    J Cell Physiol. 1989 Aug;140(2):344-58 PMID: 2745568
  22. Peptide growth factors are multifunctional.
    Nature. 1988 Mar 17;332(6161):217-9 PMID: 2831460
  23. Loss of growth factor dependence and conversion of transforming growth factor-beta 1 inhibition to stimulation in metastatic H-ras-transformed murine fibroblasts.
    Cancer Res. 1988 Dec 15;48(24 Pt 1):6999-7003 PMID: 3056609
  24. Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes.
    Int J Cancer. 1987 Apr 15;39(4):466-71 PMID: 3104215
  25. Coincidental acquisition of growth autonomy and metastatic potential during the malignant transformation of factor-dependent CCL39 lung fibroblasts.
    J Natl Cancer Inst. 1988 May 4;80(5):318-25 PMID: 3357198
  26. Autocrine growth factors and cancer.
    Nature. 1985 Feb 28-Mar 6;313(6005):745-7 PMID: 3883191
  27. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor beta (TGF-beta): conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-beta.
    Oncogene. 1991 Aug;6(8):1471-6 PMID: 1886718
  28. Tumour progression and the nature of cancer.
    Br J Cancer. 1991 Oct;64(4):631-44 PMID: 1911211
  29. Basic fibroblast growth factor in human melanoma.
    Cancer Cells. 1991 Aug;3(8):308-11 PMID: 1931440
  30. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression.
    Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6028-32 PMID: 2068080
  31. Characterization of the role of melanoma growth stimulatory activity (MGSA) in the growth of normal melanocytes, nevocytes, and malignant melanocytes.
    J Cell Biochem. 1990 Dec;44(4):207-19 PMID: 2095366
  32. A genetic model for colorectal tumorigenesis.
    Cell. 1990 Jun 1;61(5):759-67 PMID: 2188735
  33. Human glioblastoma cells release interleukin 6 in vivo and in vitro.
    Cancer Res. 1990 Oct 15;50(20):6683-8 PMID: 2208133
  34. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells.
    Cancer Res. 1990 Dec 15;50(24):7786-8 PMID: 2253221
  35. Human melanoma: development and progression.
    Cancer Metastasis Rev. 1990 Sep;9(2):101-12 PMID: 2253310
  36. Differential effects of transforming growth factor beta 1 on the growth of poorly and highly metastatic murine melanoma cells.
    Cancer Res. 1990 Jan 15;50(2):273-7 PMID: 2295066
  37. Growth-regulatory factors for normal, premalignant, and malignant human cells in vitro.
    Adv Cancer Res. 1990;54:213-34 PMID: 2404378
  38. Interleukin-6 immunoreactivity in human tumors.
    Am J Pathol. 1989 Sep;135(3):427-33 PMID: 2675620
  39. Private and public autocrine loops in neoplastic cells.
    Cancer Cells. 1989 Sep;1(1):9-17 PMID: 2701363
  40. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas.
    FEBS Lett. 1989 Jul 3;250(2):607-10 PMID: 2787758
  41. Mechanism of multidrug resistance.
    Biochim Biophys Acta. 1988 Aug 3;948(1):87-128 PMID: 2899442
  42. Transforming growth factor beta.
    Adv Cancer Res. 1988;51:107-45 PMID: 2906217
  43. Clonal dominance of primary tumours by metastatic cells: genetic analysis and biological implications.
    Cancer Surv. 1988;7(4):597-629 PMID: 3072068
  44. Reduction of TGF-beta activity abrogates growth promoting tumor cell-cell interactions in vivo.
    J Cell Physiol. 1991 Sep;148(3):380-90 PMID: 1655815
Article Info
Journal
The American journal of pathology
Abbr.
Am J Pathol
ISSN
0002-9440
Published
1992-09-00
Pages
519-24
Language
English
Region
United States
NLM ID
0370502
PMCID
PMC1886698
Subset
IM
Grants
NCI NIH HHS · CA-41233 · United States
External Links
PubMed source PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2